Sort   by:  
 Page size 
UnknownPhase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer.
Not available
S-EPMC5321045 | biostudies-literature
UnknownPhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Not available
S-EPMC4669589 | biostudies-literature
UnknownTarget-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Not available
S-EPMC4158732 | biostudies-literature
UnknownTesting for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?
Not available
S-EPMC5016094 | biostudies-literature
UnknownTargeted therapies for advanced Ewing sarcoma family of tumors.
Not available
S-EPMC4426229 | biostudies-literature
UnknownA kinase-independent biological activity for insulin growth factor-1 receptor (IGF-1R) : implications for inhibition of the IGF-1R signal.
Not available
S-EPMC3717308 | biostudies-literature
UnknownCombined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Not available
S-EPMC5882509 | biostudies-literature
UnknownSTAT3 inhibitors: finding a home in lymphoma and leukemia.
Not available
S-EPMC4012967 | biostudies-literature
UnknownPhosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Not available
S-EPMC5920739 | biostudies-literature
UnknownMulti-disciplinary management of recurrent gastrointestinal stromal tumor harboring KIT exon 11 mutation with the switch-control kinase inhibitor ripretinib and surgery.
Not available
S-EPMC10511119 | biostudies-literature
Sort   by:  
 Page size